Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
about
Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycinsCurrent treatment of atypical mycobacteriosisAssessment of treatment response in tuberculosisBactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection modelAnalysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosisVirulence of Mycobacterium tuberculosis after Acquisition of Isoniazid Resistance: Individual Nature of katG Mutants and the Possible Role of AhpCNoninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected miceSpectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection modelsConcentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosisRevisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infectionTreatment of tuberculosis with rifamycin-containing regimens in immune-deficient miceA novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosisModeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamideRoflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.The chemotherapy of tuberculosis: past, present and future.Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse ModelSerum drug concentrations predictive of pulmonary tuberculosis outcomes.The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitorDrug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.
P2860
Q27700967-AC1039E1-032F-4883-BC49-32929D01D4E7Q28265322-7885540F-3E71-4382-87DE-02DE1171962FQ28384421-C7D8CC32-9D05-460F-9A89-AE89205A9E52Q28539383-5684AFA1-6C61-4D38-9621-7779A0FA5C3EQ28540482-FD1A767F-35A7-4966-8E37-7EF82E03AF14Q28554450-15174ED3-D09E-41FD-BE73-123BA85B55BDQ30421576-2A8C193D-8E32-4122-A189-A17FD8D64A3BQ33589762-55B71749-53B5-4678-9DF3-E6783DEC92CFQ33621748-77B77F9B-A3C1-439D-B475-6AB0018EB8B1Q34092117-AC037BDC-8571-4020-991D-F4A9BFD89042Q34708437-E3E6BDD1-524B-49D3-BAFD-8938AFD996B9Q34737143-25B55D7C-BD17-4069-934E-04E960DEF2B0Q34737913-70438D95-586D-40D8-BCBB-C4009D609D67Q34922554-59F583A4-55B0-4F5B-A1FB-41037BD2C3A4Q34981779-72638565-F217-4F33-BC54-A83A30D128D3Q35042502-0250E4F2-06DE-4EA1-909E-AC4F7E5A7D45Q35076966-067A067A-FC58-4DF5-96AD-3E974CAA9B6AQ35527885-138BEE1A-C309-4F28-9221-D247B82BF26DQ35878689-BDD34A7D-E098-4B3E-8AAE-CEF7AFEBEEB1Q36171524-373ACAFF-ED6D-4D56-9AA1-DA79E2B69467Q36236341-5BFA4B39-67E7-403F-ADE9-5301FC9B077DQ36290586-D6FB01BC-BD95-4DF3-99F0-74EF5864293CQ36571928-675E188E-4446-4337-A1AC-C8AF07060F2BQ36613180-0808E54F-2341-4EC4-A270-37DD05709B66Q36821344-BCCD9FD4-EFE8-42AD-A232-037FC66078CEQ37074826-CCC8B86E-4508-4818-9FD0-D10F92836DFCQ37076746-9BF1EF7B-52A3-44C4-9359-8CB6B49C20CCQ37119985-FE632BFC-572F-4FC3-90E5-E978769EBA1DQ37213037-8E57DB7C-01AD-4199-9E9A-6F9A07C1B1B8Q37277346-46473B02-9DB1-487A-B630-10D2A23B9E6DQ37306561-58C17B8A-2691-457C-A2D6-01617F1B6C0EQ37307531-E93FCF85-AE59-4A76-9910-DA24F5ACDA7EQ37339268-8E165EC5-D576-464C-B307-E82E8C0C052AQ37339276-007A305C-D316-4128-B5AF-01FEFA6DE2D2Q37339294-2888A135-AC3A-4E7E-B6F6-07312B234F34Q38368943-AC7D2B61-E92E-42E1-81CA-EC708022D55DQ38502298-C989A6D5-1F11-44DB-A9AF-E1A4179602F1Q38754367-4F90A3FD-0449-4432-B13D-776AC8FD8A37Q40065997-2ED32479-D73A-472C-88CE-51BC424D4748Q40155324-E4041C19-0636-4810-B761-CAAA06D3A258
P2860
Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.
@en
Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.
@nl
type
label
Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.
@en
Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.
@nl
prefLabel
Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.
@en
Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.
@nl
P2093
P2860
P356
P1476
Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.
@en
P2093
Charles Peloquin
Deepak Almeida
Eric Nuermberger
Ian Rosenthal
Jacques Grosset
Kathy Williams
Rokeya Tasneen
Sandeep Tyagi
P2860
P304
P356
10.1128/AAC.00830-09
P407
P577
2009-07-20T00:00:00Z